SID 26681509

SID 26681509 is a potent, reversible, competitive, and selective inhibitor of human cathepsin L with an IC50 of 56 nM. SID 26681509 inhibits in vitro propagation of malaria parasite Plasmodium falciparum and inhibits Leishmania major with IC50s of 15.4 μM and 12.5 μM, respectively. SID 26681509 shows no inhibitory activity against cathepsin G[1].

Product Specifications

CAS Number

[958772-66-2]

UNSPSC

12352005

Target

Cathepsin; Parasite

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/sid-26681509.html

Purity

99.16

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(NNC(SCC(NC1=CC=CC=C1CC)=O)=O)[C@H](CC2=CNC3=CC=CC=C23)NC(OC(C)(C)C)=O

Molecular Formula

C27H33N5O5S

Molecular Weight

539.65

References & Citations

[1]Shah PP, et al. Kinetic characterization and molecular docking of a novel, potent, and selective slow-binding inhibitor of human cathepsin L. Mol Pharmacol. 2008 Jul;74 (1) :34-41.|[2]Pribis JP, et al. The HIV Protease Inhibitor Saquinavir Inhibits HMGB1-Driven Inflammation by Targeting the Interaction of Cathepsin V with TLR4/MyD88. Mol Med. 2015 Dec;21 (1) :749-757.

Shipping Conditions

Blue Ice

Storage Conditions

-20°C, 3 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

Cathepsin L; Leishmania; Plasmodium

Citation 01

IScience. 2024 Oct 4;27 (11) :111024.|Nat Commun. 2020 Mar 27;11 (1) :1620.|Nat Commun. 2022 May 26;13 (1) :2935.|Signal Transduct Target Ther. 2021 Mar 27;6 (1) :134.|Signal Transduct Target Ther. 2023 Oct 11;8 (1) :390.